ALK-Abelló A/S: Rhinitis trials
The registry lists 28 Rhinitis studies with ALK-Abelló A/S as lead sponsor. 2 are open to participants now and 14 have results posted.
Phase 1 1Phase 2 10Phase 3 13Phase 4 3No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic RhinitisEnrolling by invitationNCT06151938
- The Effect of Allergic Rhinitis on Educational OutcomesRecruitingNCT05881577
- Adolescent Mite Allergy Safety EvaluationCompletedNCT04541004Phase 3Results posted
- House Dust Mite Allergy Trial In ChildrenCompletedNCT04145219Phase 3Results posted
- Mite Asthma Pediatric Immunotherapy TrialCompletedNCT03654976Phase 3Results posted
- Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)CompletedNCT02256553Phase 4Results posted
- Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)CompletedNCT01700192Phase 3Results posted
- Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)CompletedNCT01678807Phase 1Results posted
- A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)CompletedNCT01644617Phase 2Results posted
- Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)CompletedNCT01549340Results posted
- A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)CompletedNCT01385371Phase 3Results posted
- Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)CompletedNCT00978029Phase 2Results posted
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)CompletedNCT00783198Phase 2/3Results posted
- Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)CompletedNCT00770315Phase 2/3Results posted
- Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)CompletedNCT00562159Phase 3Results posted
- Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)CompletedNCT00550550Phase 3Results posted
- Impact of AIT on Allergic Rhinitis and AsthmaCompletedNCT04125888
- N.I.S of AIT in Adult Patients With House Dust Mite Allergy in Real Practice in FranceCompletedNCT03746860
- Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®CompletedNCT02437786Phase 4
- Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge ChamberCompletedNCT02166268Phase 2
- Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral LyophilisateCompletedNCT01854736Phase 4
- A Dose Response Evaluation of SLITone Ultra HDM Mix ImmunotherapyCompletedNCT01728298Phase 2
- Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen RhinoconjunctivitisCompletedNCT01728285Phase 3
- An Open Trial to Assess the Tolerability of AVANZ Olive ImmunotherapyCompletedNCT01674595Phase 2/3
- An Open Trial to Assess the Tolerability of AVANZ Mite Mix ImmunotherapyCompletedNCT01568190Phase 2/3
- Comparison of Different Up-dosing Schedules With OsirisTerminatedNCT01240954Phase 2
- Grazax Asthma PreventionCompletedNCT01061203Phase 3
- Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic PatientsCompletedNCT00857779Phase 2